In Vivo Stability of Cryoprecipitate Fibrinogen

Publisher Website
Google Scholar
Abstract
Because of its lower hepatitis risk, cryoprecipitate is advocated as a substitute for commercial fibrinogen. Previous literature on cryofibrinogen demonstrated a short blood t 1/2 [half-life], rendering it unsuitable for therapeutic use. The in vivo clearance of 131I-cryoprecipitate was compared with that of 125I-standard fibrinogen. A small amount of cryoprecipitate was rapidly cleared and apparently was cryofibrinogen. The bulk of the cryoprecipitate was cleared with a normal t 1/2, as was cryoprecipitate that was in 10-bag pools. Cryoprecipitate was an effective in vivo form of fibrinogen and the preferred fibrinogen source because of its combining normal t 1/2 with single donor procurement.

This publication has 12 references indexed in Scilit: